Maribavir isomers, compositions, methods of making and methods of using
The invention relates to novel compositions and methods of using maribavir which enhance its effectiveness in medical therapy, as well as to maribavir isomers and methods of use thereof for counteracting the potentially adverse effects of maribavir isomerization in vivo in the event it occurs.
1. A method for treatment of a herpes viral infection in a patient in need thereof comprising orally administering to said patient the compound 5,6-dichloro-2-(isopropylamino)-1-(β-L-ribofuranosyl)-1H-benzimidazole, or an isomer of said compound, in an amount of 400 mg twice a day, wherein said patient is a stem cell transplant recipient.
2. The method according to claim 1 , wherein said herpes viral infection is cytomegalovirus.
3. The method according to claim 2 , wherein said compound is administered to said patient under fasted conditions.
4. The method according to claim 2 , wherein said compound is administered as a composition comprising a therapeutically acceptable adjuvant, excipient, or carrier medium.
5. The method according to claim 4 , wherein said composition is an immediate release formulation, a delayed release formulation, or a controlled release formulation.
6. A method for treatment of a herpes viral infection in a patient in need thereof comprising orally administering to said patient the compound 5,6-dichloro-2-(isopropylamino)-1-(β-L-ribofuranosyl)-1H-benzimidazole, or an isomer of said compound, in an amount of 400 mg twice a day, wherein said patient is a kidney transplant recipient.
7. The method according to claim 6 , wherein said herpes viral infection is cytomegalovirus.
8. The method according to claim 7 , wherein said compound is administered to said patient under fasted conditions.
9. The method according to claim 7 , wherein said compound is administered as a composition comprising a therapeutically acceptable adjuvant, excipient, or carrier medium.
10. The method according to claim 9 , wherein said composition is an immediate release formulation, a delayed release formulation, or a controlled release formulation.
11. A method for treatment of a herpes viral infection in a patient in need thereof comprising orally administering to said patient the compound 5,6-dichloro-2-(isopropylamino)-1-(β-L-ribofuranosyl)-1H-benzimidazole, or an isomer of said compound, in an amount of 400 mg twice a day, wherein said patient is a liver transplant recipient.
12. The method according to claim 11 , wherein said herpes viral infection is cytomegalovirus.
13. The method according to claim 12 , wherein said compound is administered to said patient under fasted conditions.
14. The method according to claim 12 , wherein said compound is administered as a composition comprising a therapeutically acceptable adjuvant, excipient, or carrier medium.
15. The method according to claim 14 , wherein said composition is an immediate release formulation, a delayed release formulation, or a controlled release formulation.
16. The method according to any one of claim 1 , 2 , 3 , 5 , or 6 - 15 , wherein the compound administered is 5,6-dichloro-2-(isopropylamino)-1-(β-L-ribofuranosyl)-1H-benzimidazole.